Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG0302-COVID19 placebo-controlled randomized double-blind Phase II/III study in healthy adults
jRCT2051200088Phase 3Active, not recruiting
- Sponsor
- AnGes, Inc.
- Start
- Nov 2020
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AG0302 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by AnGes, Inc. Primary endpoints: Incidence of treatment-emergent adverse events and Immunogenicity: anti-spike antibody geometric mean titer. Started Nov 2020; status: active, not recruiting.
02
Drugs
AG0302
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2051200088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200088.